Moderna, Inc. (NASDAQ: MRNA) has recently reported its fourth-quarter results, showcasing a performance that exceeded analysts’ expectations, which led to a remarkable surge of over 8% in its share price during intra-day trading on Friday. This increase is a positive indicator of market sentiment towards the biotechnology firm, especially in light of the challenges it has faced over recent years.
For the fourth quarter, Moderna posted a loss of $2.11 per share, which was significantly better than the analyst predictions that anticipated a loss of $2.62 per share. The company generated revenue of $678 million, slightly surpassing the consensus forecast of $662.84 million. However, this figure represents a substantial decline of 30% year over year, primarily driven by reduced sales volumes of its COVID-19 vaccines as the pandemic transitions into an endemic phase.
Looking at the broader picture, Moderna’s total revenue for the full year of 2025 was reported at $1.9 billion, a 40% decrease from the previous year, 2024. This decline was attributed to the diminishing demand for COVID-19 vaccines, which had previously been a significant revenue driver for the company. Alongside this revenue drop, Moderna reported a net loss of $2.8 billion or $7.26 per share for the year. By the end of 2025, the company maintained cash and investment reserves of $8.1 billion, which was down from $9.5 billion at the close of 2024.
Future Growth Prospects and Vaccine Pipeline
Despite the challenges faced in the previous year, Moderna remains optimistic about its future growth trajectory. The company has reaffirmed its ambitious goal of achieving up to 10% revenue growth in 2026. This growth is expected to be evenly split, with half of the revenue anticipated to come from U.S. markets and the other half from international markets. This strategic focus on diversification may help to mitigate risks associated with fluctuating vaccine demand.
In terms of its vaccine pipeline, Moderna has shared some encouraging updates. The company disclosed that its influenza vaccine filing has been accepted for regulatory review in the European Union, Canada, and Australia. However, it is noteworthy that the U.S. Food and Drug Administration issued a Refusal-to-File letter regarding the same vaccine, which underscores the regulatory challenges that can impact product launches.
Additionally, Moderna has reported significant progress in its clinical trials. The company achieved full enrollment in its Phase 3 Norovirus trial, with data anticipated to be released in 2026. This trial could pave the way for a new product offering that extends beyond COVID-19, showcasing Moderna’s commitment to addressing various infectious diseases. Furthermore, Moderna has also completed full enrollment in its Phase 2 intismeran autogene study targeting muscle invasive bladder cancer, indicating a strategic pivot towards oncology, which could expand its therapeutic portfolio.
Financial Outlook for 2026
As Moderna looks ahead to 2026, the company has outlined its expected financial landscape. It anticipates research and development expenses to be around $3.0 billion, reflecting its ongoing commitment to innovation and pipeline development. Additionally, selling, general, and administrative expenses are projected to be approximately $1.0 billion, which suggests a focus on maintaining operational efficiency as it navigates the competitive biotechnology landscape.
For year-end 2026, Moderna is projecting cash and investments to range between $5.5 billion and $6.0 billion, which highlights the importance of maintaining liquidity as it invests in research and development while also working to stabilize its revenue streams post-COVID-19.
In conclusion, while Moderna faces hurdles with declining COVID-19 vaccine sales, the company is strategically positioning itself for future growth through diversification of its product offerings and targeted investments in research. The success of its pipeline candidates and ongoing regulatory engagements will be critical in shaping the company’s financial health and market standing in the years to come.
